Analysis of Market Access Agreements in Turkey

Guvenc Kockaya, Okan Atalay, Mustafa Kurnaz, Selin Okcun, Nazlı Sencan, Cigdem Gedik, Mete Saylan, Gulpembe Oguzhan

DOI: https://doi.org/10.7175/fe.v21i1.1457

Abstract

BACKGROUND: Reimbursement agencies are increasingly adopting innovative reimbursement approaches for new and expensive technologies. Social Security Institution (SSI), Turkey`s reimbursement agency, established the Alternative Reimbursement Commission (ARC) on February 10, 2016. This study aimed to understand the implementations of market access agreements in recent years in Turkey.

METHODS: Decisions of the Health Services Pricing Commission published in the official gazette , and information from the Turkey Pharmaceuticals and Medical Devices Agency, the Abroad Drug List, Health Implementation Communique published by SSI with additional lists, such as the Annex-4A List of Reimbursed Medicines and the Annex-4C Abroad Drug Price List, were used. The data was transferred to Windows Office Excel files, and a descriptive analysis was conducted and evaluated by two market access experts.

RESULTS: There were 57 drugs included in the coverage of reimbursement with alternative reimbursement since the application was started in Turkey. 35 of them were added to Annex-4A and 22 of them to Annex-4C. Furthermore, 45.6% of the drugs had an Anatomic Therapeutic Chemical Classification (ATC) code of l-antineoplastic and immunomodulating agents, 28% were orphan drugs, 44 of them had a confidential discount rate, and financial-based agreement models were preferred for nearly all agreements.

CONCLUSIONS: Turkey has been implementing market access agreements since mid-2016. In the past 3 years, 57 drugs have been covered for reimbursement under the new implementation. Further analysis should be conducted to understand the decision-making process involved.

Keywords

Market access; Risk-sharing agreements; Reimbursement

Full Text

HTML PDF

References

  • Ministry of Health of the Republic of Turkey. Health Transformation Programme 2001. Available at https://sbu.saglik.gov.tr/Ekutuphane/Yayin/133 (last accessed May 2019)
  • Tanios N, Wagner M, Tony M, et al. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision-makers. Int J Technol Assess 2013; 29: 456-65; https://doi.org/10.1017/S0266462313000573
  • Maynard A, Bloor K. Dilemmas in the regulation of the market for pharmaceuticals. Health Affair 2003; 22: 31-41; https://doi.org/10.1377/hlthaff.22.3.31
  • Italian Trade Agency. Electro Medicals Market in Turkey. BKP Research&Consulting, 2016. Available at http://www.farexport.it/wp-content/uploads/2016/03/Elettromedicale-in-Turchia.pdf (last accessed May 2019)
  • Commission of the European Communities. Safe, innovative, and accessible medicines: A renewed vision for the pharmaceutical sector. Brussels: Commission of the European Communities. 2008
  • Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies: Past trends and future challenges (Report Id: 87). Paris: OECD Publishing, 2016
  • Bang H, Zhao H. Median-Based Incremental Cost-Effectiveness Ratio (ICER). J Stat Theory Pract 2012; 6: 428-42; https://doi.org/10.1080/15598608.2012.695571
  • Şentürk A. The effect of drug reimbursement policies on drug expenditures in the Social Security System. (Master Dissertation). Retrieved from Ulusal Tez Merkezi. 227923: 50-80
  • Fefer E. Pharmaceutical legislation and regulation. In: Embrey MA, editor. Managing access to medicines and health technologies. Sterling, Virginia: Kumarian Press, 2012. p. 100-120.
  • Embrey MA. Managing access to medicines and health technologies. 3rd ed. Sterling, Virginia: Kumarian Press, 2012
  • Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess 2008; 24: 244-58; https://doi.org/10.1017/S0266462308080343
  • Uğurlu M. Evaluation of health technologies and their role in the drug market access process. In: Kahveci R editor. Drug and market access process. Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 59-85
  • Toumi M, Jaroslawski S. Introduction to the Market Access. In. Koçkaya G, Wertheimer A, editors. Pharmaceutical market access in emerging markets. Turin: Seed, 2016. p. 3-20; https://doi.org/10.7175/747.ch1
  • Koçkaya G, Kılıç P. Pharmaceutical policies and market access. ISPOR Connections. 2012;1-3
  • Kahveci R. Drug and market access process. 1st ed. Ankara: SAGE Yayıncılık, 2017
  • Koçkaya G. Introduction to market access. 2018. Available at http://sepd.org.tr/wp-content/uploads/2018/01/G%C3%BCven%C3%A7-Ko%C3%A7kaya-Pazar-Eri%C5%9Fime-Giri%C5%9F-v2.ppt (last accessed May 2019)
  • Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26: 551-6; https://doi.org/10.2165/00019053-200826070-00002
  • Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU (Rapor No:461). Brussels: European Commission, 2012; https://doi.org/10.2139/ssrn.2161803
  • Kharvi S, Pakkala TPM, Srinivasan G. Ordering policies under currency risk-sharing agreements: A Markov chain approach. Opsearch 2019; 1-20; https://doi.org/10.1007/s12597-019-00394-z
  • Koçkaya G. Value-based pricing within drug pricing methods. In: Kahveci R, editor. Drug and market access process. Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 126-133.
  • OECD. Pensions at a Glance 2017: OECD and G20 Indicators. Paris: OECD Publishing, 2017. p. 122-3
  • Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: The European experience. LSE. 2013. Available at http://eprints.lse.ac.uk/50513/ (last accessed May 2019)
  • Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010; 96: 179-90; https://doi.org/10.1016/j.healthpol.2010.02.005
  • Dinç M. Overview of pharmaceutical reimbursement system in Turkey and evaluation of transition process to alternative reimbursement models. (Master Dissestation). Retrieved from Ulusal Tez Merkezi. 489688: 16-43
  • Lorente R, Antonanzas F, Rodriguez-Ibeas R. Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists. Health Economics Review 2019; 9: 25; https://doi.org/10.1186/s13561-019-0242-x
  • Garrison Jr LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implemention, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013; 16: 703-19; https://doi.org/10.1016/j.jval.2013.04.011
  • Beykoz V. Performance-based models. In: Kahveci R, editor. Drug and market access process. Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 141-7
  • Walker S, Sculpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper 77. Center for Health Economics. 2012; https://doi.org/10.1016/j.jval.2011.12.013
  • Walker S, Sculpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper 77. University of York: Centre for Health Economics, 2012. Available at https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_development.pdf (last accessed May 2019)
  • Medicare’s Coverage With Evidence Development: A Policy-Making Tool in Evolution. J Oncol Pract 2007; 3: 296-301; https://doi.org/10.1200/JOP.0763501
  • Espin J, Rovira J, Garcia L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. Brussels: Commissioned by the European Commission, Directorate-General Enterprise, 2011
  • Vitry A, Roughead E. Managed entry agreements for pharmaceutical in Australia. Health Policy 2014; 117: 345-52; https://doi.org/10.1016/j.healthpol.2014.05.005
  • Dokuyucu Ö. Financial-based models. In: Kahveci R, editor. Drug and market access process, Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 148-52
  • Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012; 5: 38-46; https://doi.org/10.2174/1876824520130426001
  • Demir C. Evaluation of the views and preferences of stakeholders on the drug policies implemented in Turkey by using the Multi-Criteria Decision Making Method (ELECTRE III). (Master Dissestation). Retrieved from Ulusal Tez Merkezi. 509928:65-82
  • Official Gazette. Social Security Institution General Health Insurance Alternative Reimbursement Regulation. 2016. Number: 29620. Available at http://www.resmigazete.gov.tr/eskiler/2016/02/20160210-6.htm (last accessed Apr 2019)

Statistics

Abstract: 112 views
HTML: 45 views
PDF: 32 views

Refbacks

  • There are currently no refbacks.




© SEEd srl